Literature DB >> 26622737

SMAD4 expression in breast ductal carcinoma correlates with prognosis.

Nannan Liu1, Chunyan Yu1, Yanfen Shi2, Jing Jiang3, Yuhe Liu1.   

Abstract

The present study examined SMAD4 expression in fine-needle aspiration cell blocks from patients with breast ductal carcinoma, in order to assess its viability as a prognostic marker. Using immunohistochemistry, the SMAD4 protein status of 86 breast ductal carcinoma fine-needle biopsies, from patients who underwent tumor resection at Beihua University Affiliated Hospital (Jilin, China) between 2002 and 2008, was characterized. The association between SMAD4 expression and clinicopathological parameters, as well as prognosis was assessed using the Mantel-Haenszel method and Cox proportional hazards regression. SMAD4 staining was observed in the cytoplasm and nucleus, and its expression was found to be decreased in ductal breast carcinoma as compared with adjacent normal breast epithelia. Patients with reduced SMAD4 expression levels tended to exhibit more poorly differentiated tumors, a higher risk of recurrence and shorter overall survival. These results demonstrated that the evaluation of SMAD4 protein status in fine-needle biopsy specimens of breast ductal carcinoma may provide additional prognostic information.

Entities:  

Keywords:  SMAD4; ductal breast carcinoma; immunochemistry assay

Year:  2015        PMID: 26622737      PMCID: PMC4533521          DOI: 10.3892/ol.2015.3442

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.

Authors:  Thomas E Rohan; Shu-Qiu Li; Robert Hartwick; Rita A Kandel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

2.  Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression.

Authors:  Li-Hui Wang; Seok-Hyung Kim; Jung Hyun Lee; Yoon-La Choi; Young Chul Kim; Tae Sung Park; Yun-Chul Hong; Chun-Fu Wu; Young Kee Shin
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

3.  Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors.

Authors:  Leilei Yang; Chunming Mao; Yan Teng; Wenlong Li; Jishuai Zhang; Xuan Cheng; Xiaobing Li; Xinghai Han; Zhaofan Xia; Hongkui Deng; Xiao Yang
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

4.  Role of transforming growth factor-beta signaling in cancer.

Authors:  M P de Caestecker; E Piek; A B Roberts
Journal:  J Natl Cancer Inst       Date:  2000-09-06       Impact factor: 13.506

5.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Authors:  E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

6.  Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.

Authors:  Shinichi Tsutsui; Hiroshi Inoue; Kazuhiro Yasuda; Kosuke Suzuki; Hidefumi Higashi; Shoichi Era; Masaki Mori
Journal:  Oncology       Date:  2005-07-12       Impact factor: 2.935

7.  Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line.

Authors:  John Jakob; Satoru Nagase; Adi Gazdar; Minchen Chien; Irina Morozova; James J Russo; Subhadra V Nandula; Vundavalli V V S Murty; Chi-Ming Li; Benjamin Tycko; Ramon Parsons
Journal:  Genes Chromosomes Cancer       Date:  2005-04       Impact factor: 5.006

8.  Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas.

Authors:  Dylan V Miller; Alexey A Leontovich; Wilma L Lingle; Vera J Suman; Maureen L Mertens; James Lillie; Kimberly A Ingalls; Edith A Perez; James N Ingle; Fergus J Couch; Daniel W Visscher
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

9.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Authors:  S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

View more
  5 in total

1.  High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.

Authors:  Zhi-Gang Cao; Jun-Jing Li; Ling Yao; Yan-Ni Huang; Yi-Rong Liu; Xin Hu; Chuan-Gui Song; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2016-10-04

2.  Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4.

Authors:  Neoh Hun Phuah; Mohamad Nurul Azmi; Khalijah Awang; Noor Hasima Nagoor
Journal:  Mol Cells       Date:  2017-04-12       Impact factor: 5.034

3.  miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression.

Authors:  Xiu-Hua Yang; Feng Guo
Journal:  Mol Med Rep       Date:  2018-03-07       Impact factor: 2.952

4.  Estimation of the proteomic cancer co-expression sub networks by using association estimators.

Authors:  Cihat Erdoğan; Zeyneb Kurt; Banu Diri
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

5.  Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.

Authors:  Marie-Julie Nokin; Justine Bellier; Florence Durieux; Olivier Peulen; Gilles Rademaker; Maude Gabriel; Christine Monseur; Benoit Charloteaux; Lieven Verbeke; Steven van Laere; Patrick Roncarati; Michael Herfs; Charles Lambert; Jean Scheijen; Casper Schalkwijk; Alain Colige; Jo Caers; Philippe Delvenne; Andrei Turtoi; Vincent Castronovo; Akeila Bellahcène
Journal:  Breast Cancer Res       Date:  2019-01-23       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.